The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease
Open accessAbstract
Huntington's disease (HD) is a progressive neurodegenerative illness for which there is no effective therapy. We examined whether creatine, which may exert neuroprotective effects by increasing phosphocreatine levels or by stabilizing the mitochondrial permeability transition, has beneficial effects in a transgenic mouse model of HD (line 6/2). Dietary creatine supplementation significantly improved survival, slowed the development of brain atrophy, and delayed atrophy of striatal neurons and the formation of huntingtin-positive aggregates in R6/2 mice. Body weight and motor performance on the rotarod test were significantly improved in creatine-supplemented R6/2 mice, whereas the onset of diabetes was markedly delayed. Nuclear magnetic resonance spectroscopy showed that creatine supplementation significantly increased brain creatine concentrations and delayed decreases in N-acetylaspartate concentrations. These results support a role of metabolic dysfunction in a transgenic mouse model of HD and suggest a novel therapeutic strategy to slow the pathological process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We found that creatine significantly improves survival, improves motor performance, slows the development of brain atrophy, increases brain ATP levels, delays atrophy of striatal neurons and the formation of Htt-positive aggregates in the R6/2 and N-171-82Q transgenic mouse models of HD118-120.”
From Mitochondrial Approaches for Neuroprotection (2008) · cites this paper as [120]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Mouse Brain in Stereotaxic Coordinates
Paxinos, G. (2001) · Cited by 12,859
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
Shah, M. A., Datson, N. A., Srinidhi, L., Stanton, V. P., MacDonald, M. E., Allard, M. W., Youngman, S., Am, F., Mott, R., Draths, K., et al. (1993) · Cell · Cited by 3,055
Self-citationAggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain
DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P., & Aronin, N. (1997) · Science · doi:10.1126/science.277.5334.1990 · Cited by 2,439
Neuropathological Classification of Huntingtonʼs Disease
VONSATTEL, J.-P., MYERS, R. H., STEVENS, T. J., FERRANTE, R. J., BIRD, E. D., & RICHARDSON, E. P. (1985) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198511000-00003 · Cited by 2,227
Self-citationDavies, S. W., Turmaine, M., Cozens, B. A., DiFiglia, M., Sharp, A. H., Ross, C. A., Scherzinger, E., Wanker, E. E., Mangiarini, L., & Bates, G. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80513-9 · Cited by 2,188
Wallimann, T., Wyss, M., Brdiczka, D., Nicolay, K., & Eppenberger, H. M. (1992) · Biochemical Journal · doi:10.1042/bj2810021 · Cited by 2,011
Spatial Localization in NMR Spectroscopy in Vivo
Bottomley, P. A. (1987) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1987.tb32915.x · Cited by 1,382
Nuclear and Neuropil Aggregates in Huntington’s Disease: Relationship to Neuropathology
Gutekunst, C.-A., Li, S.-H., Yi, H., Mulroy, J. S., Kuemmerle, S., Jones, R., Rye, D., Ferrante, R. J., Hersch, S. M., & Li, X.-J. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-07-02522.1999 · Cited by 914
Self-citation
Research works printed but not linked: 1
- Gutekunst, 1996, Mitochondrial calcium homeostasis in Huntington's disease fibroblasts., Soc Neurosci Abstr, 22, 227
Cited by
Sorted by citations
Items 501–518 of 518
Myocyte Androgen Receptor Modulates Body Composition and Metabolic Parameters
Fernando, S. M. (2010) · TSpace (University of Toronto)
Beeks, A. O. (2016) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
O envolvimento de proteínas quinases na facilitação do aprendizado espacial induzido por creatina
Souza, M. A. (2009) · Americanae (AECID Library)
Aljaroudi, A. (2018) · Memorial University Research Repository (Memorial University)
Cyclosporin A Protects Striatal Neurons from Mitochondrial Dysfunction
Leventhal, L., & Kordower, J. H. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-315-6_8
Browne, S. E., & Beal, M. F. (2001) · Elsevier eBooks · doi:10.1016/b978-012351830-9/50051-2
Self-citationGreenwood, M., Leutholtz, B., & Kreider, R. B. (2004) · CRC Press eBooks · doi:10.1201/9780203507704.ch6
The paradigm of Huntington’s disease: Therapeutic opportunities in neurodegeneration
Leegwater‐Kim, J., & Cha, J.-H. J. (2004) · Neurotherapeutics · doi:10.1007/bf03206573
Kreider, R. B. (2007) · CRC Press eBooks · doi:10.1201/9781420008500.ch9
Neuroprotective effects of creatine in the CMVMJD135 mouse model of Spinocerebellar Ataxia type 3
Silva, S. C. D., Carvalho, A. A. N., Cunha, C. I. S., Silva, J. M., Castro, A. C. T., Vieira, R., Fernandes, A. S., & Maciel, P. (2018) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Lima, E. C. S. B., Maia, A. S. S., Silva, P. L., Tancredi, E., Teruel, M. S., & Ribeiro, C. (2025) · Nutraceuticals · doi:10.3390/nutraceuticals6010001 · Cited by 1
Étude de l'implication potentielle des marqueurs du striatum dans la maladie de Huntington
Galvan, L. (2011) · theses.fr (ABES) · doi:10.70675/ebf9c275z3ce2z474dz8d5az68c2c35df509
A Study of Striatal Markers as Disease Modifiers in Huntington's Disease
Francelle, L. (2014) · theses.fr (ABES) · doi:10.70675/ac372f63z7712z4632z8782z6b71a643add2
Study of vesicular glycolysis in health and Huntington's Disease
Cluskey, M. M. (2021) · theses.fr (ABES) · doi:10.70675/eb022640z9c3cz4467z940dz6b27765c296b
Wiprich, M. T., Vasques, R. D. R., Zaluski, A. B., Bertoncello, K. T., Altenhofen, S., Gusso, D., Rodrigues, G., Sachett, A., Piato, Â., Maito, F. L. D. M., et al. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111840
Sobów, T., & Sławek, J. W. (2007) · Aktualności Neurologiczne
Metadata
- Authors
- Ferrante, R. J., Andreassen, O. A., Jenkins, B. G., Dedeoglu, A., Kuemmerle, S., Kubilus, J. K., Kaddurah-Daouk, R., Hersch, S. M., & Beal, M. F.
- Affiliations
- Boston University (US)
- Harvard University (US)
- Emory University (US)
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2000-06-15
- Volume
- 20
- Issue
- 12
- Pages
- 4389-4397
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC6772461
- OpenAlex
- W1750171938
- Cited by
- 522
- References
- 62
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 7 · 2023: 8 · 2022: 7 · 2021: 10 · 2020: 6 · 2019: 12 · 2018: 10 · 2017: 9 · 2016: 23 · 2015: 7 · 2014: 23 · 2013: 14 · 2012: 21
- FWCI
- 16.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Hereditary Disease Foundation
- National Institutes of Health (5r29ns037102-02, AG13846)
- National Institute on Aging (P30AG013846, P01AG012992)
- National Institute of Neurological Disorders and Stroke (NS37102, NS 35255, NS38180, R01NS035255)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- Huntington's disease, creatine supplementation, neuroprotection, R6/2 transgenic mice, phosphocreatine, mitochondrial permeability transition, brain atrophy, striatal neurons, huntingtin aggregates, N-acetylaspartate, diabetes onset, motor performance
- MeSH terms
- Huntingtin Protein, Animals, Aspartic Acid, Atrophy, Brain, Corpus Striatum, Creatine, Crosses, Genetic, Female, Humans, Huntington Disease, Magnetic Resonance Imaging, Male, Mice, Inbred Strains, Motor Activity, Nerve Tissue Proteins, Neurons, Nuclear Proteins, Neuroprotective Agents, Dietary Supplements, Animals, Genetically Modified, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
